BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

European equity markets may thrive with monetary easing, fiscal expansion, and controlled inflation, despite risks from ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

This commitment marks a critical step in ensuring the sustainability and responsiveness of WHO as it continues its mission to address a growing range of health crises worldwide.

A pragmatic approach to streamlining technology and innovating processes will help advance clinical data management.

When Page Campbell's doctor recommended she try an injectable prescription drug called Wegovy to lose weight before scheduling bariatric surgery, she readily agreed.

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’ - Edward Fanelli, 57, shared his regrets about taking Ozempic after he was diagnosed ...